Overview

A Study of CC-97540 in Participants With Severe, Refractory Systemic Lupus Erythematosus (SLE)

Status:
Not yet recruiting
Trial end date:
2028-02-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory Systemic Lupus Erythematosus (SLE).
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Cyclophosphamide
Fludarabine